论文部分内容阅读
目的:观察BEAC方案作为预处理方案联合自体干细胞移植(autologous stem cell transplantation,ASCT)治疗非霍奇金淋巴瘤(non-Hodgkin’s lymphoma,NHL)的疗效。方法:选取2000-01-2011-12新疆医科大学附属肿瘤医院收治的NHL患者共45例,采用BEAC方案联合ASCT治疗,动员方案为依托泊苷(Vp-16)联合粒细胞集落刺激因子(G-CSF)。41例患者采用BEAC联合ASCT方案作为巩固治疗,4例采用BEAC联合ASCT方案作为挽救治疗。结果:45例患者均移植成功,重建造血功能。不良反应均可耐受,无移植相关死亡。移植前CR 53.3%(24/45),PR 46.7%(21/45),移植后CR 73.3%(33/45),PR 26.7%(11/45)。中位随访时间为41个月(8~139个月),至随访截止日期6例因疾病进展死亡,1例因第二原发肿瘤死亡。5年生存率为83.3%。结论:BEAC预处理方案联合ASCT方案治疗NHL安全性高,疗效较好。
OBJECTIVE: To observe the efficacy of BEAC as a pretreatment regimen in the treatment of non-Hodgkin’s lymphoma (NHL) with autologous stem cell transplantation (ASCT). Methods: A total of 45 patients with NHL admitted to Cancer Hospital Affiliated to Xinjiang Medical University from January 2000 to December 2011 were enrolled in this study. BEAC combined with ASCT was used. The mobilization protocol was etoposide (Vp-16) combined with granulocyte-colony stimulating factor -CSF). Forty-one patients underwent BEAC combined with ASCT regimen as consolidation therapy and four as BEAC combined with ASCT regimen as salvage therapy. Results: All the 45 patients were successfully transplanted and the hematopoietic function was reconstructed. Adverse reactions can be tolerated without transplant-related deaths. Pretransplant CR 53.3% (24/45), PR 46.7% (21/45), post-transplant CR 73.3% (33/45), PR 26.7% (11/45). The median follow-up time was 41 months (range, 8 to 139 months). Six patients died of disease progression and one died of the second primary tumor at the follow-up deadline. The 5-year survival rate was 83.3%. Conclusion: BEAC pretreatment combined with ASCT regimen for the treatment of NHL is safe and effective.